Cite
Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.
MLA
Ravix, Anne, et al. “Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.” Cancers, vol. 16, no. 12, June 2024, p. 2193. EBSCOhost, https://doi.org/10.3390/cancers16122193.
APA
Ravix, A., Bandiera, C., Cardoso, E., Lata-Pedreira, A., Chtioui, H., Decosterd, L. A., Wagner, A. D., Schneider, M. P., Csajka, C., & Guidi, M. (2024). Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study. Cancers, 16(12), 2193. https://doi.org/10.3390/cancers16122193
Chicago
Ravix, Anne, Carole Bandiera, Evelina Cardoso, Adrian Lata-Pedreira, Haithem Chtioui, Laurent Arthur Decosterd, Anna Dorothea Wagner, Marie Paule Schneider, Chantal Csajka, and Monia Guidi. 2024. “Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.” Cancers 16 (12): 2193. doi:10.3390/cancers16122193.